Objective:Implantableportthrombosis(IPT)incancerpatientsisarelativelyrarebutseverecomplication.Severalfactorsarereportedlyassociatedwiththeoccurrenceofthrombosis.WeaimedtodescribetheprevalenceandtheanatomoclinicalfeaturesofIPTobservedincancerpatientswhoweretreatedinamedicaloncologydepartmentinTunisia.Methods:Atotalof600cancerpatientswhohadportimplantationfromJanuary2013toDecember2015wereretrospectivelyidentified.Caseswithsymptomatic/incidentalIPT(radiologicallyconfirmed)werefurtheridentified.Epidemiologicalandanatomoclinicalfeatureswerecollectedfrompatientrecordsandthedepartmentdatabase.Results:Weobservedthat33ofthe600patientshadIPT;thus,theprevalencewas5.5%.Themedianagewas57years,andthegenderratiowas0.43.Overweightorobesitywasobservedin73%ofthepatients.IPToccurredmainlyinpatientswithbreast(36.4%)andcolorectal(33.3%)cancers,whichweremostlynonmetastatic(79%).Atleastoneidentifiedclassicalthromboembolicriskfactorwasfoundin13patients(smokingin9,tamoxifenin2).IPTwassymptomaticin93%ofthecases,occurringwithinanaveragetimeof56days.Implantableportswereremovedbecauseofinfectionin2casesandnonfunctionalityin3cases.IPTtreatmentwasbasedonlow-molecular-weightheparins(94%)andantivitaminK(6%)foranaverageof130days.Fourpatientshadpost-therapycomplications:onethrombosisrecurrenceandthreeinfections.Conclusions:IPTcasesinthe600patientswereobservedtooccurinobesenonmetastaticcancerpatientswithinthefirst3monthsafterIPimplantation.
